The effect of purslane on the heart of dialysis patients

Investigating the effect of hydroalcoholic extract of purslane plant compared to placebo on the level of cardiac biomarkers in dialysis patients: a double-blind clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220317054323N2

Enrollment

Registered

2025-02-15

Start date

2025-02-19

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

??????? ???? ?????. Chronic kidney disease, stage 4 (severe)

Interventions

Intervention 1: Intervention group: using hydroalcoholic extract of purslane plant with a dose of 500 mg, orally, twice a day for 4 weeks. Intervention 2: Control group: receiving placebo along with s

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Dialysis for at least 3 months Perform dialysis at least 2 times a week

Exclusion criteria

Exclusion criteria: Presence of active malignancy Uncontrolled active infection

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Aspartate Aminotransferase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Creatine Kinase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Lactate Dehydrogenase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Pro- Brain Natriuretic Peptide. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Blood Urea Nitrogen. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Creatinine. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Cholesterol. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Triglyceride. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Troponin I. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.	—

Measure

Time frame

Alanine Aminotransferase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Aspartate Aminotransferase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Creatine Kinase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Lactate Dehydrogenase. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Pro- Brain Natriuretic Peptide. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Blood Urea Nitrogen. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Creatinine. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Cholesterol. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Triglyceride. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.;Troponin I. Timepoint: Before and Immediately After the Intervention. Method of measurement: Laboratory Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRozina Abbasi Larki

Yasouj University of Medical Sciences

kian1380@yahoo.com+98 74 3323 5153

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026